thyrotoxicosis and myxedema-anesthetic implications
TRANSCRIPT
![Page 1: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/1.jpg)
Thyrotoxicosis and Myxedema-Preoperative preparation and
Intraoperative complications and Management
R.Srihari
![Page 2: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/2.jpg)
Topics for Discussion
• Thyrotoxicosis: – Etiology– Signs and Symptoms– Diagnosis– Treatment– Management of
Anesthesia– Thyroid Storm
• Myxedema:– Etiology– Signs and Symptoms– Diagnosis– Treatment– Management of
Anesthesia– Myxedema Coma
![Page 3: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/3.jpg)
Thyrotoxicosis
• Introduction– Thyrotoxicosis:
• State of thyroid hormone excess
– Hyperthyroidism:• State of excessive thyroid function
• Major etiologies of thyrotoxicosis are hyperthyroidism caused by primary and secondary causes
![Page 4: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/4.jpg)
Etiology
• Thyotoxicosis caused by hyperthyroidism:– Graves Disease– Toxic MNG– Toxic adenoma– Struma ovari– TSH secreting pituitary
adenoma– Chorionic gonadotropin
secreting tumours– Iodine overdose
• Thyrotoxicosis caused by hypothyroidism:– Drug induced thyroiditis– Subacute thyroiditis
![Page 5: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/5.jpg)
Clinical Manifestations
• Symptoms:– Hyperactivtity and
Irritability– Palpitations– Fatigue and Weakness– Weight loss with
increased appetite– Diarrhoea– Polyuria– Oligomenorrhoea with
loss of libido
• Signs:– Tachycardia– Atrial Fibrillation– Tremors– Goitre– Warm, moist skin– Muscle weakness– Proximal myopathy– Lid retraction– Cardiomyopathy (severe)
![Page 6: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/6.jpg)
• Graves’ Disease:– Associated with Graves’ ophthalmopathy and
dermopathy
– Graves’ Ophthalmopathy:• Dalrymple sign• Von Grafe sign• Joffroy sign• Moebius sign
![Page 7: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/7.jpg)
• NO SPECS scheme – acronym derived from following eye changes:– N – no changes– O – only signs, no symptoms (lid retraction/lag)– S – Soft tissue involvement (Periorbital edema)– P – Proptosis (>22m)– E – Extraocular muscle involvement (diplopia)– C – Corneal involvement– S – Slight loss
![Page 8: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/8.jpg)
– Thyroid dermopathy:• Almost always seen with Graves ophthalmopathy• Overall incidence < 5%
• Although most frequent over anterior and lateral aspects of lower leg( aka pretibial myxedema)
Skin changes can occur at any site esp. after trauma
• Typical lesion – non inflamed, indurated plaque with deep purple/pink color and orange skin appearance
– Thyroid acropachy:• Clubbing seen in Thyrotoxicosis pt (<1%) – strongly a/w Thyroid dermopathy
![Page 9: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/9.jpg)
• Investigations:– CBC Microcytic anemia with thrombocytopenia– ECHO/Ecg if cardiac symptoms +– S. Creatinine (if patient more 60 yrs)– IDL to r/o pre-existing vocal cord palsy– CT scan of neck– Flow volume loop– Thyroid function tests
![Page 10: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/10.jpg)
Treatment
• Hyperthyroidism of Graves’ Disease is treated by decreasing thyroid hormone synthesis – Using antithyroid drugs
OR– Reducing the amount of thyroid tissue
OR– Thyroidectomy
![Page 11: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/11.jpg)
• Antithyroid drugs:– Main drugs Thionamides
PTU/Carbimazole/MethimazoleAct by inhibiting TPO decreasing oxidation and
organification Decreasing Antithyroid antibody levelsPTU also inhibits T4T3
![Page 12: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/12.jpg)
• Carbimazole/ Methimazole :– 10-20 mg Q8h-Q12h initially once euthyroid 10-20mg OD Duration of action- 6 hours
• PTU:– 100-200mg Q6h-Q8h dose decreased as thyrotoxicosis improves
• TFTs and clinical manifestation are reviewed 3-4 weeks after starting treatment
• Euthyroid state seen 6-8 weeks following therapy
• Remission rates seen after 18-24 months following therapy
![Page 13: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/13.jpg)
• Common side effects of anti-thyroid drugs:– Rash – Urtacaria May resolve spontaneously– Fever or substituting with alternatives– Arthralgia
• Rare but major side effects:– Hepatitis– SLE like vasculitis– Agranulocytosis confirmed with complete blood count
![Page 14: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/14.jpg)
• Propanolol:– 20-40 mg Q6h– Helps to control adrenergic symptoms especially in early stages
brfore antithyroid drugs take effect– Alternatives: atenolol
• Sodium ipodate/ iopanoic acid:– 500mg- 3g OD– Mainly used in adequate response to treatment/relapse– Progressive destruction of thyroid cells and can be used as
initial treatment or for relapses after a trial of antithyroid drugs– Pregnancy: Contraindicated
![Page 15: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/15.jpg)
– Iodine in high concentration inhibit release of hormones from hyperfunctioning gland effect occurs immediately but lasts only for several weeks
Hence preserved for preserved for • preparing hyperthyroid patients for surgery • Management of patients with thyrocardiac disease
– High concentrations of iodide reduce all phases of thyroid synthesis and release result in decreased gland size and vascularity
– Admininistered orally as SSKI 3 drops Q8h 10-14 days
![Page 16: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/16.jpg)
• Surgery:– Indicated only after patient returns to euthyroid
state Anithyroid drugs should be continued
– Anticoagulants/ Coumarins:• Used if Atrial fibrillation present
![Page 17: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/17.jpg)
Management of Anesthesia
• Preparation :– Extremely important– For elective surgery all patients should be made
euthyroid with course of antithyroid drugs for 6-8 weeks preoperatively • Low TSH levels should not be a contraindication to surgery
– TSH levels remain suppressed from prolonged hyperthyroidism in patients who have normalised T3 and T4 levels
• SSKI – given 7-14 days prior to Sx• Beta blockers to control heart rate perioperatively
![Page 18: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/18.jpg)
– For emergency surgery:• Antithyroid drug should be administered even though it
has limited effect if taken less than 2 weeks• Antithyroid drugs should preceed iodide by 2-3 hours• IV beta blockers (Esmolol -0.5mg/kg infusion 0.03-
0.3mg/kg/min)• Sodium ipodate 500mg BD• Dexamethasone – 2mg q6h
• Euthyroid state usually achieved in 5-7 days
![Page 19: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/19.jpg)
• Preoperative Preparation:– Premedication: Barbiturates/BZDs/Narcotics
NO ATROPINE
– Monitoring: • SpO2, BP, HR,eTCO2 and temperature• IBP in patients with uncontrolled thyroid condition• Central line if large amounts of blood loss anticipated
![Page 20: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/20.jpg)
• Induction:– Thiopentone –preferred– Ketamine –avoided– Propofol- large doses to be given
• Muscle relaxants: the following can be used safely– SCh– Rocuronium– Vecuronium
![Page 21: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/21.jpg)
• Maintenance of anesthesia:– Should be kept in deeper plane of anesthesia– MAC not affected – Isoflurane and Sevoflurane- ideal with N20 + O2
• Agents to correct hypotension:– IVF– Phenylephrine
• Eye protection- very important
• Reversal of anesthesia:– Glyco + Neostigmine
![Page 22: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/22.jpg)
• Removal of thyrotoxic gland does not mean immediate resolution of thyrotoxicosis– T1/2 of T4 7-8 days
– Hence beta blocker therapy may be need to be continued post-operative period
– Antithyroid drug therapy can be discontinued
![Page 23: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/23.jpg)
Thyroid Storm
• Introduction :– Most serious compication of hyperthyroidism with
mortality ranging from 10-75% of hospitalised patients
– Most common in patients with poorly controlled Graves’ Disease
– Clinical diagnosis acute disruption of the normal steady state of circulating hormones
![Page 24: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/24.jpg)
• Precipitating Factors:– Infection/Sepsis– Withdrawal of anti-thyroid drugs– Surgery/Trauma– Parturition– DKA– Iodinated contrast dyes– Hypoglycemia– Excessive manipulation of thyroid gland– Burns
![Page 25: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/25.jpg)
• Clinical features:– Fever + Tachycardia Most common
– Fever: Most characteristic >41 C
– CVS:• Tachycardia• Atrial fibrillation, Ventricular arrhytmias• Heart failure• Hypertension with wide pulse pressure(early), Hypotension (late)
![Page 26: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/26.jpg)
• Neuromuscular:– Tremors– Encepalopathy– WeaknessCan progress to CVA/ Status epilepticus/Thyrotoxic
myopathy/Rhabdomyolysis
• GI:– Nausea/ Vomiting/ Diarhoea– Jaundice (indicated hepatocellular injury- poor prognosis)
• Respiratory– Dyspnea– Increased eTCO2 and O2 consumption Aggravated with pulmonary oedema/ respiratory muscle weakness and
tracheal obstruction from goitre
![Page 27: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/27.jpg)
• Lab testing:– Increased FT3/FT4– Hyperglycemia– Leucocytosis– Abnormal LFT– Reduced K/Mg ; Increased Ca inc bone
resorption
![Page 28: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/28.jpg)
• Management:– Treatment aimed at:• Control and relief of adrenergic symptoms• Control of thyroid function abnormality• Stopping Precipitating factor• Investigation and treatment of underlying thyroid
disease• Supportive measures
![Page 29: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/29.jpg)
• Beta blockers:– Mainstay of controlling adrenergic symptoms– IV propanolol – 0.5-1mg increments over 10 minutes while
monitoring CV response decreases sympathetic hyperactivity+Inhibits conversion of T4 T3 +Concurrent administration of enteral propanolol with doses of 60-120mg Q4h to Q6h to enhance elimination during thyroid crisis
– Esmolol loading dose -250-500 mcg/kg infusion 50-100mcg/kg/min allows titration with minimal side effects
![Page 30: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/30.jpg)
– Thionamides:• These drugs block de novo synthesis of thyroid hormones within
1-2 hours of administration But no effect on release of preformed Glandular store of Thyroid Hormone
• PTU- Drug of choice – 200mg Q4h• Methimazole -100mg stat foll by 20mg Q8h
– Iodine:• Release of glandular store of thyroid hormone inhibited by
administering Iodine/Lithium• Should be given only after Thionamides given after 1 hour or it
will exacerbate Storm• SSKI -10 drops Q8h (8mg iodide/iodine per drop)
![Page 31: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/31.jpg)
– Amidarone:• Blocks peripheral conversion of T4 T3
+Decreased concentration of T3 induced adrenoceptors in cardiac
myocytes
– Bile acid sequesterants:• Thyroid hormone are metabolised in the liver where they are
conjugated with glucoronide and sulfate excreted in bile which are reabsorbed in intestine
• Cholestyramine(4g Q6h) interferes the thyroid hormone reabsorption in enterohepatic circulation
![Page 32: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/32.jpg)
• Steroids:– Decrease T4 T3 conversion– Modulate auto-immune process during Thyroid crises– Inj. Hydrocortisone 100mg Q8h or Inj. Dexa 4mg iv Q6h
– Supportive therapy:• Fluid management• Nutrition• Drug therapy salicylates and Frusemide AVOIDED • Precipitating factors• Plasmapheresis LAST RESORT
![Page 33: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/33.jpg)
Myxedema
• Etiology:– Primary:
• Iodine Deficiency• Hasimoto’s• Iatrogenic- !odine 131 deficiency/ Total thyroidectomy• Drugs: Iodine excess/ Amiodarone/ Antothyroid drugs• Infiltrative disorders: Amyloidosis/ Sarcoidosis
– Secondary:• Hypopituitarism• Isolated TSH deficiency
![Page 34: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/34.jpg)
Clinical Manifestations • Symptoms:
– Tiredness, weakness– Dry skin– Feeling cold– Difficulty concentrating/poor
memory– Constipation– Weight gain with poor appetite– Dypnea– Hoarseness of voice– Menorrhagia– Hearing Loss
• Signs:– Dry coarse skin– Cool peripheral extremities– Puffy face,palms– Diffuse alopecia– Peripheral edema– Carpal tunnel syndrome– Delayed tendon reflexes– Myocardial contractility +
decreased PR decreased Stroke volume and bradycardia with increased peripheral vascular resistance
![Page 35: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/35.jpg)
– Non-pitting edema: seen due to accumulation of hydrophilic mucopolysaccharides in dermis and other areas :• Tongue• Vocal cords – hoarseness of voice
![Page 36: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/36.jpg)
Investigations
– Findings in Hypothyroidism:• Thyroid function test• Increased CPK• Elevated cholesterol and triglycerides• Macrocytic anemia• Adynamic ileus• ECG: low amplitude P wave and QRS complexes +
flattened/ inverted T waves + Sinus bradycardia
![Page 37: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/37.jpg)
Treatment– L-thyroxine- given for treatment of hypothyroidism
consistent potency, reliably restores levels of T4 and T3 to normal and has prolonged duration of action
– Gradual onset with half life of 7-8 days
– If no residual thyroid function, daily replacement dose 1.6mcg/kg (~100-150mcg/day)
– In patients who develop hypothyroidism after treatment of Graves’ Disease necessary to replace with 75-125mcg/day
![Page 38: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/38.jpg)
• Adults <60 years without evidence of heart disease may be started on 50-100 mcg/day daily
Dose is adjusted on basis of TSH levels goal of treatment being normal TSH / less than normal
TSH responses are gradual and should be measured at 2 months after instituting therapy or after any subsequent change in levothyroxine dosage
![Page 39: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/39.jpg)
• Clinical effects after initiation of therapy are slow to appear Pts may not experience full relief from symptoms 3-6 months after TSH is normal
• Adjustments is made in 12.5 to 25 mcg increments if TSH is high
• Once full replacement is obtained and TSH stable- follow up – yearly
• Important component of therapy Compliance to Rx
![Page 40: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/40.jpg)
• For elderly or those with CAD starting dose of 25 mcg/kg increasing monthly by 25 mcg till euthyroidism is achieved
• Patients with hypothyroid cardiomyopathy improvement in cardiac function in 2-4 months on 100mcg /day of L-thyroxine
• Subclinical hypothyroidism treatment started only if– TSH increased persistently for 3 months– TSH>10 mU/l– If TPO Ab+ve
![Page 41: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/41.jpg)
Management of Anesthesia
• Preoperative Issues:– Patients with overt hypothyoidism should be treated prior to
elective surgery
– In emergency , if Surgery can be delayed for 24-48 hours iv T3 can be given (peak action-24-38 hours)
– Because of increased adrenocortical insufficiency + decreased hormone response to stress hypothyroid patients should receive hydrocortisone cover during periods of increased surgical stress
![Page 42: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/42.jpg)
– Hypothyroid patients may be at increased risk when receiving either general or regional anesthesia:• Airway compromise secondary to swollen oral cavity
with large tongue• Edematous vocal cords• Goitrous enlargement• Decreased gastric emptying increasing risk of
regurgitation and aspiration
![Page 43: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/43.jpg)
• Hypodynamic cardiovascular system:– Low cardiac output/ Stroke volume/ heart rate/
baroreceptor reflexes and intravascular volumeCompromised by surgical stress and cardiac
depressant anesthetic agents
– Hypothermia occurs quickly and is difficult to prevent and treat
![Page 44: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/44.jpg)
– Hematological and Metabolic abnormalities:• Anemia• Platelet and coagulation factor abnormalities• Hypoglycemia• Hyponatremia
– Increased sensitivity to volatiles dec CO
– PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM DO NOT PRESENT ANY ANESTHETIC PROBLEM
![Page 45: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/45.jpg)
• If pt is planned for emergency surgery– Increased risk of cardiovascular instability
intraoperatively– Myxedema coma postoperatively
• Preoperative Sedation:– Contraindicated in hypothyroid patients for elective
surgery increased sensitivity to sedative drugs
![Page 46: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/46.jpg)
• REGIONAL ANESTHESIA IS RECOMMENDED WHERE THERE ARE NO CONTRAINDICATIONS
• Monitoring:– Routine– Swan-Ganz if severe hemodynamic impairment with
TEE -> to assess intravascular volume
• IVF of choice DNS
![Page 47: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/47.jpg)
– Induction agents:• Ketamine• Barbiturates and BZDs – in titrated doses
– Muscle relaxants:• Sch• Intermediate NDMR: Vecuronium and Rocuronium
– Opioids:• Short acting fentanyl and its derivatives
![Page 48: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/48.jpg)
– Maintenance:• N20:O2 + Volatiles carefully used esp. in hypovolemia
blunted barorecptor response
– Intraop monitoring:• Temperature• Electrolyte and Fluid status• Invasive monitors in patients undergoing major surgery• Peripheral nerve stimulator
– Warming: very important
![Page 49: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/49.jpg)
– Exaggerated hypotension:• Common and should be treated with judicious fluid and
inotropes and vasopressors – Ephredrine– Dopamine– Epinephrine
• NO PURE ALPHA 1 AGONIST
• IF unresponsive steroids should be given
![Page 50: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/50.jpg)
• Ventilation:– Should be controlled – not spontaneous As hypoventilation seen due to increased
sensitivity to anesthetic drugs
Delayed recovery is common and postoperative ventilation may be required
![Page 51: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/51.jpg)
Myxedema Coma• Introduction:
– Myxedema coma extreme manifestation of hypothyroidism although rare
Mortality 30-50%
– Term misnomer
– Condition considered in patients presenting with reduced level of consciousness with hypothermia
– Most common in elderly women with long standing undiagnosed or undertreated hypothyroidism, in whom an additional significant stress is experienced
![Page 52: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/52.jpg)
– Precipitating Factors:• Infections• Cold environment• Burns• Stroke• Surgery• Trauma• CHF• Co2 retension
![Page 53: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/53.jpg)
– Clinical manifestation:• Decreased mental status• Hypothermia• Clinical features of hypothyroidism
– CVS– RS– Airway– GI– Metabolic
– Though TBW is increased intravascular volume decreased
![Page 54: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/54.jpg)
• Treatment:– Mainstay of Rx:• Thyroid replacement therapy• Steroid replacement• Supportive measures
![Page 55: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/55.jpg)
– Thyroid Replacement Therapy:• All patients with suspected myxedema coma should
receive presumptive treatment with thyroid hormones
• Severity of clinical presentation does not correlate with doses of replacement hormone required– Rapid replacement: a/w life threatening myocardial ischemia
and arrhythmias– Delayed replacement: exposes prolonged risk of complication
from crises
![Page 56: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/56.jpg)
– Loading doses 200-400 mcg iv saturates binding proteins
Followed by 50-100 mcg daily till conversion
– Steroid replacement:• Corticosteroids important part of treatment as
relative/ absolute hypoadrenalism may occur concurrent with hypothyroid disease• Inj. Hydrocortisone 100mg iv Q8h (or) Inj. Dexa 4mg iv
Q6h S.Cortisol level should be collected prior to starting
therapy (Inj. Hydrocortisone) if normal ..Rx stopped
![Page 57: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/57.jpg)
– Supportive Treatment:• Hypothermia warming where possible
• Cardiac output monitoring guide fluid therapy
• Hyponatremia reversible with thyroxine treatment If severe - fluid restriction + Hypertonic saline
• Hypoglycemia 25% Dextrose via central venous line
• Precipitating factor should be corrected
• DVT prophyllaxis
• Ulcer prophyllaxis
• Mechanical ventilation
![Page 58: Thyrotoxicosis and myxedema-Anesthetic implications](https://reader035.vdocuments.mx/reader035/viewer/2022070520/58f249311a28ab52748b4569/html5/thumbnails/58.jpg)
Thank you